KRAS and non-small cell lung carcinoma: A possible mechanism of intrinsic resistance to FTIs may be the alternative prenylation of KRAS by GGTase; preclinical data regarding the activity of FGTI-2734, a dual FTase and GGTase inhibitor, on KRAS mutant cell lines (including a NSCLC line) are promising (80).